CO14. A pivotal study evaluating efficacy and safety of the hedgehog pathway inhibitor (HPI) vismodegib (GDC-0449) in patients with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC)
- 1 June 2011
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Melanoma Research